Alzamend Neuro (ALZN) Competitors $2.42 -0.02 (-0.82%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$2.43 +0.01 (+0.41%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. PMN, AKTX, CVKD, DARE, ALLR, TENX, RNTX, MIRA, TRIB, and ASBPShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Promis Neurosciences (PMN), Akari Therapeutics (AKTX), Cadrenal Therapeutics (CVKD), Dare Bioscience (DARE), Allarity Therapeutics (ALLR), Tenax Therapeutics (TENX), Rein Therapeutics (RNTX), MIRA Pharmaceuticals (MIRA), Trinity Biotech (TRIB), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Its Competitors Promis Neurosciences Akari Therapeutics Cadrenal Therapeutics Dare Bioscience Allarity Therapeutics Tenax Therapeutics Rein Therapeutics MIRA Pharmaceuticals Trinity Biotech Aspire Biopharma Promis Neurosciences (NASDAQ:PMN) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk. Does the media prefer PMN or ALZN? In the previous week, Alzamend Neuro had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 1 mentions for Alzamend Neuro and 0 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.87 equaled Alzamend Neuro'saverage media sentiment score. Company Overall Sentiment Promis Neurosciences Very Positive Alzamend Neuro Very Positive Is PMN or ALZN more profitable? Alzamend Neuro's return on equity of -181.34% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Promis NeurosciencesN/A -266.69% -131.59% Alzamend Neuro N/A -181.34%-116.84% Do analysts prefer PMN or ALZN? Promis Neurosciences presently has a consensus price target of $4.33, suggesting a potential upside of 707.55%. Alzamend Neuro has a consensus price target of $45.00, suggesting a potential upside of 1,759.50%. Given Alzamend Neuro's higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Promis Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, PMN or ALZN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPromis NeurosciencesN/AN/A$2.78M-$0.21-2.56Alzamend NeuroN/AN/A-$4.51MN/AN/A Which has more risk & volatility, PMN or ALZN? Promis Neurosciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Do institutionals & insiders have more ownership in PMN or ALZN? 50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 6.1% of Promis Neurosciences shares are owned by company insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryAlzamend Neuro beats Promis Neurosciences on 5 of the 9 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.07M$3.12B$5.74B$9.77BDividend YieldN/A2.28%6.66%4.50%P/E RatioN/A20.8682.9826.39Price / SalesN/A396.75537.51110.52Price / CashN/A43.5325.7028.92Price / Book0.498.1011.056.58Net Income-$4.51M-$53.35M$3.28B$265.84M7 Day Performance-1.63%-0.29%-0.17%-0.26%1 Month Performance10.00%9.18%8.35%5.82%1 Year Performance-88.80%10.11%53.92%22.47% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro3.4148 of 5 stars$2.42-0.8%$45.00+1,759.5%-88.6%$7.07MN/A0.004News CoveragePositive NewsUpcoming EarningsPMNPromis Neurosciences3.1718 of 5 stars$0.54+1.8%$4.33+696.6%-60.7%$28.19MN/A-2.595AKTXAkari Therapeutics3.4098 of 5 stars$0.88-1.1%$5.00+471.4%-81.7%$28.16MN/A0.009Short Interest ↑CVKDCadrenal Therapeutics3.4404 of 5 stars$13.57+10.1%$32.00+135.8%+63.1%$27.82MN/A-1.534News CoverageShort Interest ↓Gap UpDAREDare Bioscience2.1593 of 5 stars$2.05-1.4%$12.00+485.4%-43.3%$27.77M$10K-0.9630ALLRAllarity Therapeutics2.8557 of 5 stars$1.88+100.0%$9.00+378.0%-70.6%$27.68MN/A0.0010High Trading VolumeTENXTenax Therapeutics1.7489 of 5 stars$6.02+1.7%$17.00+182.4%+50.3%$27.45MN/A-6.549RNTXRein TherapeuticsN/A$1.16-1.7%N/AN/A$27.03MN/A-0.439Positive NewsGap DownMIRAMIRA Pharmaceuticals3.2329 of 5 stars$1.41-1.1%$17.00+1,110.0%-27.5%$26.79MN/A-2.872Short Interest ↓TRIBTrinity Biotech0.7922 of 5 stars$1.48-4.8%N/A-85.9%$26.62M$61.56M-0.50480News CoverageShort Interest ↑ASBPAspire BiopharmaN/A$0.53-4.2%N/AN/A$26.08MN/A0.00N/APositive NewsGap Down Related Companies and Tools Related Companies Promis Neurosciences Competitors Akari Therapeutics Competitors Cadrenal Therapeutics Competitors Dare Bioscience Competitors Allarity Therapeutics Competitors Tenax Therapeutics Competitors Rein Therapeutics Competitors MIRA Pharmaceuticals Competitors Trinity Biotech Competitors Aspire Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALZN Stock Alerts